NL2009514C2 - Pharmaceutical composition comprising methadone hydrochloride. - Google Patents

Pharmaceutical composition comprising methadone hydrochloride. Download PDF

Info

Publication number
NL2009514C2
NL2009514C2 NL2009514A NL2009514A NL2009514C2 NL 2009514 C2 NL2009514 C2 NL 2009514C2 NL 2009514 A NL2009514 A NL 2009514A NL 2009514 A NL2009514 A NL 2009514A NL 2009514 C2 NL2009514 C2 NL 2009514C2
Authority
NL
Netherlands
Prior art keywords
pharmaceutical composition
methadone
composition according
methadone hydrochloride
present
Prior art date
Application number
NL2009514A
Other languages
Dutch (nl)
Inventor
Niels Freriks
Johanna Elisabeth Maria Vermeer
Dani L Mioch
Original Assignee
Eurovet Animal Health B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurovet Animal Health B V filed Critical Eurovet Animal Health B V
Priority to NL2009514A priority Critical patent/NL2009514C2/en
Application granted granted Critical
Publication of NL2009514C2 publication Critical patent/NL2009514C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Description

Pharmaceutical composition comprising methadone hydrochloride
The present invention relates to a multidose composition containing racemic methadone hydrochloride suitable.
5 Methadone hydrochloride, the structural formula of which is: h3c. ch3
N
_ Jy-CHa
10 / \_v and enantiomer , HCI
^Γ“· 15 is a known active ingredient in human and veterinary medicinal products for anaesthesia and analgesia. In human medicine it is used to treat addiction.
US5578645 discloses a method for treating addiction to narcotic drugs in a mammal comprising administering to the mammal a therapeutically effective amount of a solution comprising racemic methadone and at least one branched chain amino acid 20 wherein the methadone is administered in a dosage amount of from about 10 to 80 mg/kg of body weight/day.
EP 1020183 discloses a preparation orally administered which is regulated in releasing an analgesic from microtablets, permits the dose equal to individually and accurately releasing a drop agent from a storage medical case and can be distributed to 25 the number of base capable of readily and accurately regulating a prescribed amount of an effective substance. The preparation which is regulated in releasing at least one kind of analgesics from microtablets with a diameter not more than 3 mm is disclosed. It is favourable that the analgesic is comprised of at least one kind of opioids (e.g. hydromorphone, oxycodone, morphine, levorphanol, methadone, dihydrocodein or the 30 like), the microtablet contains an analgesic homogeneously dispersed in a sustained-release matrix and the matrix includes at least one kind of polymer (e.g. cellulose ether and the like), waxes, fats, oils, fatty alcohols or their corresponding esters.
2
None of the methadone compositions of the prior art are multi dose formulations.
The present invention provides for a solution to the disadvantage of the prior art compositions.
5 The present inventors have found that a pharmaceutical composition comprising racemic methadone or a salt thereof as an active ingredient, and a preservative provide s for a solution to said problem.
In an embodiment of the present invention the preservative is a none therapeutically active preservative.
10 The composition according to the present invention is a solution comprising racemic methadone hydrochloride and a preservative and is suitable for use in equidae. Preferably the composition according to the present invention is used as a sedative and/or an analgesic in the treatment of pain.
The preservative is preferably chosen from the group consisting of 15 parabens, but not limited to this group. Parabens have the general formula:
O^OR
20
V
OH
25 The advantage of a composition according to the present invention is that it is a multi-dose formulation that can be used in combination with other active substances in horses. As methadone is an opioid it is subject to global narcotic legislation. Veterinarians and doctors must keep track of each use of methadone. Any disposal of the product must be justified and described in a logbook. The use of a multi-dose formulation 30 leads to less disposal of methadone. This allows the user to fulfil narcotic legislation effectively. The multi-dose formulation furthermore contributes to the safe use of this opioid and to the safety of the environment.
3
In a preferred embodiment the preservatives a selected from the group consisting of methyl parahydroxybenzoate and propyl parahydroxybenzoate since the inventors found that these parabens have the best antimicrobial activity in the preferred applicable pH range of 4-8. These parabens have a broad spectrum of antimicrobial 5 activity and these parabens act synergistic. These parabens are widely used in cosmetics, food products and pharmaceutical preparations and are therefore recognized to be safe.
Preferably a pharmaceutical composition according to the present invention comprises racemic methadone hydrochloride as an active ingredient. An embodiment of the invention relates to a combination of racemic methadone hydrochloride, to be used in 10 therapy, and at least one other therapeutically active ingredient. Preferably, said active ingredient are selected from the group consisting of: Benzodiazepine (e.g. midazolam), dissociative (e.g. ketamine), tranquilizer (e.g. acepromazine), NSAID (meloxicam) and sedative ( e.g. a2-agonist).
Moreover, the invention also relates to a use of the present racemic 15 methadone hydrochloride for the manufacture of a medicine for sedation and/or treatment of pain. According to the invention, said medicine can also contain at least one other therapeutically active ingredient. Preferably, said other therapeutically active ingredient is selected from the group consisting of: Benzodiazepine (e.g. midazolam), dissociative (e.g. ketamine), tranquilizer (e.g. acepromazine), NSAID (meloxicam) or a2-agonist (e.g. 20 xylazine, detomidine).
The present pharmaceutical formulation, combination of pharmaceutical composition containing it, is to be administered to a subject in need of a treatment therewith. In an embodiment of the present invention the pharmaceutical composition is a veterinary pharmaceutical composition.
25 In particular, the subject is a patient, human or mammal, such as a horse, suffering from pain, troubles or needing surgery. The amount of the racemic methadone hydrochloride of the invention, also referred to herein as the active ingredient, which is required to achieve a therapeutic effect, that is the therapeutically effective amount, will vary with the severity of the pain, the route of administration and the age and other 30 conditions of the subject.
For a horse, suitable dosages are between 0.05 mg/kg and 0.5 mg/kg body weight of the subject.
4
The desired dose may be presented as one, two, three or more sub-doses administered at appropriate intervals throughout the day.
While it is possible for the active ingredient to be administered as such, it is preferable to present it as a pharmaceutical formulation. Accordingly, the present 5 invention provides a pharmaceutical formulation comprising methadone hydrochloride, together with a pharmaceutically acceptable preservative and optionally another therapeutic agent. The carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof. Suitable excipients are described in standard manuals, e.g., in the Handbook of 10 Pharmaceutical Excipients, 6th ed. Rowe, Sheskey en Quinn.
The invention further includes a pharmaceutical formulation, as hereinbefore described, in combination with packaging material suitable for the pharmaceutical formulation, said packaging material including instructions for therapeutically using of the pharmaceutical formulation.
15 Formulations are in particular those suitable for but not limited to parenteral administration.
The formulations may be prepared by any method well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al., Remmington: The Science and Practice of Pharmacy, 20th Edition, Lippincott, Williams 20 and Wilkins, 2000; see especially part 5: pharmaceutical manufacturing. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Such accessory ingredients include those conventional in the art, such as Sodium chloride.
Formulations suitable for administration may be presented as a solution, an 25 emulsion or a suspension. The formulation may also be administered as a bolus.
In the context of the present invention, the use of methadone hydrochloride in a therapeutic context does not exclude the use of any other active ingredient for treatment of the condition to be treated. The other active ingredient can be administered before, simultaneously with, or after methadone hydrochloride according to the invention. 30 Methadone hydrochloride can even be combined together with the other active compound into one pharmaceutical composition. The expert will recognise that, in each case of combined use or add - on therapy, the doses and/or formulations may have to be adapted accordingly.
5
The subject-matter of the appended claims are also part of the content of the description. The present invention is further illustrated by the following non-limiting example.
5 EXAMPLE
The following composition is an example of a composition according to the present invention (see Table 1).
Table 1.
10 Amount/ ml
Ingredient Manufacturer composition Function
Macfarlan Smith Active
Methadone hydrochloride' Ltd. 10 mg substance
Methyl . _ parahydroxybenzoate Clariant 1 mg Preservative 1 ο
Propyl parahydroxybenzoate Clariant 0,2 mg Preservative
Sodium chloride Merck 7,2 mg Tonicity agent
Water 1 ml Solvent 20 * 10.0 mg Methadone hydrochloride is equivalent to 8.9mg of methadone.
The pH of the composition can be adjusted with hydrochloric acid and sodium hydroxide.
25 30

Claims (9)

1. Farmaceutische samenstelling die racemisch methadon of een zout daarvan en een conserveermiddel omvat.A pharmaceutical composition comprising racemic methadone or a salt thereof and a preservative. 2. Farmaceutische samenstelling volgens conclusie 1 die methadon hydrochloride omvat.A pharmaceutical composition according to claim 1 comprising methadone hydrochloride. 3. Farmaceutische samenstelling volgens conclusie 1 of 2 waarbij het conserveermiddel is gekozen uit de groep die bestaat uit parabenen.The pharmaceutical composition according to claim 1 or 2, wherein the preservative is selected from the group consisting of parabens. 4. Farmaceutische samenstelling volgens een of meer ven de voorgaande 10 conclusies, waarbij de samenstelling een oplossing is en bij voorkeur een waterige oplossing, emulsie of suspensie is.Pharmaceutical composition according to one or more of the preceding claims, wherein the composition is a solution and preferably is an aqueous solution, emulsion or suspension. 5. Farmaceutische samenstelling volgens een of meer van de voorgaande conclusies, waarbij de farmaceutische samenstelling een veterinaire farmaceutische samenstelling is.A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is a veterinary pharmaceutical composition. 6. Farmaceutische samenstelling volgens een of meer van de voorgaande conclusies als sedatief of een analgeticum.Pharmaceutical composition according to one or more of the preceding claims as a sedative or an analgesic. 7. Farmaceutische samenstelling volgens een of meer van de voorgaande conclusies als sedatieve of analgetische voor paardachtigen.Pharmaceutical composition according to one or more of the preceding claims as a sedative or analgesic for equidae. 8. Farmaceutische samenstelling volgens een of meer van de voorgaande 20 conclusies, waarbij de samenstelling een multidosis samenstelling is.Pharmaceutical composition according to one or more of the preceding claims, wherein the composition is a multi-dose composition. 9. Farmaceutische samenstelling volgens een of meer der voorgaande conclusies, waarbij het farmaceutische preparaat voor parenterale toediening is. 25 2009514Pharmaceutical composition according to one or more of the preceding claims, wherein the pharmaceutical preparation is for parenteral administration. 25 2009514
NL2009514A 2012-09-25 2012-09-25 Pharmaceutical composition comprising methadone hydrochloride. NL2009514C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL2009514A NL2009514C2 (en) 2012-09-25 2012-09-25 Pharmaceutical composition comprising methadone hydrochloride.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2009514 2012-09-25
NL2009514A NL2009514C2 (en) 2012-09-25 2012-09-25 Pharmaceutical composition comprising methadone hydrochloride.

Publications (1)

Publication Number Publication Date
NL2009514C2 true NL2009514C2 (en) 2014-03-27

Family

ID=51582015

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2009514A NL2009514C2 (en) 2012-09-25 2012-09-25 Pharmaceutical composition comprising methadone hydrochloride.

Country Status (1)

Country Link
NL (1) NL2009514C2 (en)

Similar Documents

Publication Publication Date Title
RU2428985C2 (en) Drug form containing oxycodon and naloxon
Simon et al. The present and future of opioid analgesics in small animal practice
US7645767B2 (en) Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20180318237A1 (en) Topical regional neuro-affective therapy in mammals with cannabinoids
JP2016053085A (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20230414572A1 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
AU2023251499A1 (en) Combinations of opioids and N-acylethanolamines
US11925635B2 (en) Methods and compositions for maintaining opioid efficacy in the treatment of pain
KR20090125748A (en) Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
AU2006315201A1 (en) Synergistic combinations of norketamine and opioid analgesics
NL2009514C2 (en) Pharmaceutical composition comprising methadone hydrochloride.
JP2012516288A (en) Drug abuse inhibitor, method and composition
US11771662B2 (en) Analgesic formulation for control of pain in dogs
MX2011001631A (en) Treatment of anxiety disorders.
WO2020023879A1 (en) Use of neurokinin-1 antagonists to treat pruritus associated with atopic dermatitis
Moro et al. Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy
Doyle et al. (359) GRK2 constitutively downregulates delta opioid receptor activity in the periphery
Nagilla Stereospecific pharmacokinetics of ketorolac in large animal species: Evaluation of an implantable delivery system in dogs
KR20100126441A (en) Combination comprising a cannabinoid receptor binding compound and an opioid
MX2008006610A (en) Pharmaceutical compositions
BG109702A (en) Combination of deramciclane and opioids as analgesics